More Reuters
View Older Stories View Newer Stories-
Analysis-Lebanon's distressed debt soars to shaky new heights
-
SoftBank, OpenAI Japan AI joint venture is delayed, source says
-
Analysis-Anglo-Teck merger to unlock Chile mine synergies, if Glencore signs off
-
Games-Japan considering North Korea's participation in 2026 Asian Games
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Santos stock slumps as $18.7 billion ADNOC-led deal collapses
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
Roche to acquire liver drug developer 89bio for up to $3.5 billion
-
U.S. diplomats on Syria abruptly let go amid pro-Damascus policy push, sources say
-
U.S. diplomats on Syria abruptly let go amid pro-Damascus policy push, sources say
-
U.S. diplomats on Syria abruptly let go amid pro-Damascus policy push, sources say
-
U.S. diplomats on Syria abruptly let go amid pro-Damascus policy push, sources say
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
-
Foreigners snap up Asian bonds in August after two-month hiatus
